Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients

Authors

  • Matthias Mehling MD,

    1. Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine
    2. Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department, and University Hospital Basel, Basel, Switzerland
    Search for more papers by this author
  • Patricia Hilbert MD,

    1. Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine
    Search for more papers by this author
  • Stefanie Fritz MSc,

    1. Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department, and University Hospital Basel, Basel, Switzerland
    Search for more papers by this author
  • Bojana Durovic MD, PhD,

    1. Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department, and University Hospital Basel, Basel, Switzerland
    Search for more papers by this author
  • Dominik Eichin BSc,

    1. Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department, and University Hospital Basel, Basel, Switzerland
    Search for more papers by this author
  • Olivier Gasser PhD,

    1. Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department, and University Hospital Basel, Basel, Switzerland
    Search for more papers by this author
  • Jens Kuhle MD,

    1. Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine
    Search for more papers by this author
  • Thomas Klimkait PhD,

    1. Institute of Medical Microbiology, University of Basel, Basel, Switzerland
    Search for more papers by this author
  • Raija L.P. Lindberg PhD,

    1. Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine
    Search for more papers by this author
  • Ludwig Kappos MD,

    Corresponding author
    1. Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine
    • Department of Neurology and Department of Biomedicine, University Hospital Basel, 4 Petersgraben, CH-4031 Basel, Switzerland
    Search for more papers by this author
    • Phone: +41 (0)61 265 44 64, Fax: +41 61 265 41 98

  • Christoph Hess MD, PhD

    Corresponding author
    1. Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department, and University Hospital Basel, Basel, Switzerland
    • Medical Outpatient Department and Department of Biomedicine, University Hospital Basel, 4 Petersgraben, CH-4031 Basel, Switzerland
    Search for more papers by this author

Abstract

T cells exit secondary lymphoid organs along a sphingosine1-phosphate (S1P) gradient and, accordingly, are reduced in blood upon fingolimod-mediated S1P-receptor (S1PR)-blockade. Serving as a model of adaptive immunity, we characterized cellular and humoral immune responses to influenza vaccine in fingolimod-treated patients with multiple sclerosis (MS) and in untreated healthy controls. Although the mode of action of fingolimod might predict reduced immunity, vaccine-triggered T cells accumulated normally in blood despite efficient S1PR-blockade. Concentrations of anti–influenza A/B immunoglobulin (Ig)M and IgG also increased similarly in both groups. These results indicate that fingolimod-treated individuals can mount vaccine-specific adaptive immune responses comparable to healthy controls. Ann Neurol 2011

Ancillary